ANI Pharmaceuticals, Inc. (ANIP)
| Market Cap | 1.86B +25.1% |
| Revenue (ttm) | 923.71M +37.0% |
| Net Income | 84.43M |
| EPS | 3.90 |
| Shares Out | 22.75M |
| PE Ratio | 20.97 |
| Forward PE | 8.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,135,275 |
| Open | 87.76 |
| Previous Close | 83.91 |
| Day's Range | 79.37 - 87.76 |
| 52-Week Range | 56.71 - 99.50 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 110.00 (+34.38%) |
| Earnings Date | May 8, 2026 |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, gr... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ANIP stock is "Strong Buy." The 12-month stock price target is $110.0, which is an increase of 34.38% from the latest price.
News
ANI Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 20% revenue growth and 24% adjusted EBITDA growth, driven by Rare Disease and Generics, with Cortrophin Gel revenues up 42% year-over-year. 2026 guidance was raised, and a $100M share repurchase program was announced.
ANI Pharmaceuticals reports Q1 non-GAAP EPS $2.05, consensus $1.30
Reports Q1 revenue $237.46M, consensus $207.63M. “We delivered a strong first quarter, generating $237.5M in revenue and $63.0M in adjusted non-GAAP EBITDA, with solid performance across all business ...
ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance
PRINCETON, N.J., May 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the first quarter ended Ma...
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results...
ANI Pharmaceuticals announces FDA approval, launch of Pimozide Tablets
ANI Pharmaceuticals (ANIP) announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI’s Pimozide Tablets is the generic version of the reference listed drug Orap. U.S. annual sales
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets i...
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg ...
ANI Pharmaceuticals launches Isosorbide Mononitrate Tablet USP
ANI Pharmaceuticals (ANIP) announced that following final approval from the FDA for its Abbreviated New Drug Application, or ANDA, the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administrati...
ANI Pharmaceuticals announces publication of iluvien clinical trial results
ANI Pharmaceuticals (ANIP) announced publication of the results from the NEW DAY clinical trial involving iluvien – fluocinolone acetonide intravitreal implant -, 0.19 mg for use in appropriate patien...
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving I...
ANI Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Rare Disease assets now drive 60% of revenue, with Cortrophin and ILUVIEN showing strong growth and long-term durability due to large underpenetrated markets and patent protection. Generics and Brands provide cash flow for reinvestment, while expanded sales teams and strategic initiatives support continued momentum.
ANI Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Strong 2025 results and robust 2026 guidance highlight rare disease as the main growth driver, with Cortrophin Gel expansion and a new sales force targeting acute gouty arthritis. ILUVIEN's growth is supported by new data and label expansion, while operating leverage is expected in 2027.
ANI Pharmaceuticals Transcript: 47th Annual Raymond James Institutional Investor Conference
The company projects over $1 billion in 2026 sales, with rare disease driving 60% of revenue and Cortrophin Gel as the lead growth asset. Generics continue to deliver strong cash flow, funding expansion and clinical initiatives, while financial strength supports ongoing transformation.
ANI Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 results with 44% revenue growth and 47% adjusted EBITDA growth, led by rare disease and generics. 2026 guidance targets over $1B in revenue, with Cortrophin Gel and generics as key drivers and significant investments in sales force expansion and clinical evidence generation.
ANI Pharmaceuticals reports Q4 adjusted EPS $2.33, consensus $1.98
Reports Q4 revenue $247.1M, consensus $231.03M. “2025 was a year of significant growth for our Rare Disease and Generics businesses, which drove expansion to both our top- and bottom-line,” said
ANI Pharmaceuticals sees FY26 adjusted EPS $8.83-$9.34, consensus $8.64
Sees FY26 revenue $1.055B-$1.115B, consensus $1.04B. Sees FY26 adjusted EBITDA $275M-$290M.
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and ye...
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with ...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 fin...
ANI Pharmaceuticals price target raised to $124 from $115 at Guggenheim
Guggenheim raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $124 from $115 and keeps a Buy rating on the shares, primarily driven by an increase to the firm’s
ANI Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Rare disease is set to drive over 60% of 2026 revenues, led by Purified Cortrophin Gel’s 55%-65% growth and a major expansion into acute gouty arthritis. Generics remain a strong cash generator, funding rare disease investments, while Iluvien’s growth is targeted through new commercial strategies and access initiatives.
ANI Pharmaceuticals sees FY26 revenue $1.055B-$1.115B, consensus $955.04M.
Provides full year 2026 financial guidance, which includes: Total net revenues of $1.055B-$1.115B; Cortrophin Gel net revenues of $540M-$575M; Adjusted non-GAAP EBITDA of $275M-$290M; Rare Disease bus...
ANI Pharmaceuticals sees FY23 EPS, revenue ‘within or above guidance ranges’
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854M-$873M, $221M-$228M and $7.37-$7.64, respecti...
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228...